Objective: Accelerated gastric emptying of solids may play a role in the pathogenesis of obesity. Orlistat, a potent lipase inhibitor, induces fat malabsorption and body weight loss but might accelerate gastric emptying as a result of suppressed CCK release. The aim was to investigate the role of fat restriction and lipase inhibition in CCK release and gastric emptying. Subjects: A total of 28 patients (three male (M)/25 female (F); mean (s.d.) BMI 37.4(3.9) kg/m 2 ) entering a randomized, double-blind, placebo-controlled study. Measurements: CCK release and gastric emptying by scintigraphy at the start (T0), after 1 month of an energy-and fatrestricted diet and placebo (T1), and after 1 month (T2) and 1 year (T3) of randomization to placebo or 120 mg orlistat three times a day. Results: One month of dieting and a weight loss of 2.3 kg (2.1% of initial weight) did not affect gastric emptying of liquids and solids. Basal and meal-stimulated CCK levels remained unaltered. Placebo-treated subjects who continued the diet for 1 month demonstrated a borderline significant suppressed CCK secretion and a weight loss of 1.2 kg (1.0%) without an effect on gastric emptying. After 1 year, the CCK secretion recovered to or beyond values at the start. A significantly slower emptying of solids (17.6 (T3) versus 25.9 (T1)%/h) and a weight loss of 10.4 kg (9.9%) was observed. Subjects on 120 mg orlistat lost 2.5 kg (2.5%) after 1 month, and 9.8 kg (9.9%) after 1 year. Basal and postprandial CCK release decreased significantly after the first month of orlistat treatment but normalized after 1 year. Diet and lipase inhibition did not have any influence on gastric emptying. Conclusion: Energy and fat restriction of 1 month did not alter gastric emptying in the whole group. Continuation of the diet for 1 year resulted in a delayed gastric emptying of solids. Lipase inhibition did not result in a sustained depressed CCK release and the anticipated acceleration of gastric emptying did not occur.
Obesity, a chronic and incurable disease of global epidemic proportions, affects the gastrointestinal tract and contributes to gastroesophageal reflux disease, gallstones and cholecystitis, pancreatitis, non-alcoholic fatty liver disease and gastrointestinal malignancies. The digestive tract may also play a role in the pathogenesis of the disease. The physiology of food intake and satiety has been investigated in relation to gastric emptying, intestinal transit, rate of nutrient absorption, gastrointestinal hormone release, and nutrient and cholecystokinin (CCK) receptor sensitivity. In obese subjects, gastric emptying of solids and liquids has been compared with normal-weight subjects with inconclusive results of a faster, 1-5 normal [6] [7] [8] [9] [10] [11] [12] or delayed emptying. 13, 14 This discrepancy can be explained by the different methods used to study gastric emptying (intubation techniques, ultrasound, scintigraphy with single or dual isotopes) and by a lack of standardization of the timing, energy content, macronutrient composition and size of the test meal. 12, 15, 16 Orocecal transit has been reported to be normal or delayed 8, 9, 17, 18 and the rate of absorption in the first 70 cm of small bowel to be enhanced in comparison with normal-weight subjects. 1, 8 A downregulation of intestinal nutrient responsive mechanisms and CCK receptors has been reported as well. 9 Also, changes in gastric emptying induced by weight loss, 2, 4, 11, 12 anorectic drugs [19] [20] [21] [22] or bariatric surgery [23] [24] [25] [26] have been observed. The initial faster solid emptying reverted towards normal-weight values after weight loss or remained unchanged. 2, 4, 11 Drugs such as (dex)fenfluramine, mazindol and ephedrine have been shown to combine their anorectic effects with an inhibition of the gastric evacuation. [19] [20] [21] [22] Orlistat, a chemically derived hydrogenated derivative of lipstatin, a natural product of Streptomyces toxytricini, is a potent and specific inhibitor of gastric and pancreatic lipase and carboxylester lipase through covalent binding to serine, the active site in the enzyme. In a dose-dependent way, orlistat has been shown to inhibit the absorption of fat and to increase fecal fat excretion and thus, to induce a significant weight loss in addition to an energy-restricted diet. [27] [28] [29] Theoretically, the inhibition of lipase activity might have unwanted effects as well, such as a suppressed CCK release and an accelerated gastric emptying. Some fat hydrolysis takes place in the stomach by the action of lingual and gastric lipase 30 which is crucial in setting the stage for CCK release from CCK-producing cells in the proximal small intestine. The release of CCK is perpetuated by fatty acids, liberated through the action of pancreatic lipase-colipase and carboxylester lipase. 31 Hildebrand et al. 32 showed that with increasing doses of orlistat (0-30-60-120 mg), an increasing inhibition of lipase activity resulted in a decreased fatty acid liberation and CCK release. CCK has several effects such as gallbladder contraction, exocrine pancreatic enzyme secretion, inhibition of gastric emptying, acceleration of intestinal transit, stimulation of insulin secretion, induction of satiety and reduction of food intake. 33 A decreased CCK release might therefore less profoundly inhibit gastric emptying and result in an accelerated gastric emptying. The effects of orlistat on gastric emptying and/or CCK release have been investigated in normal-weight healthy volunteers and diabetic overweight subjects. [34] [35] [36] [37] These studies were all acute, unphysiologic experiments (with gastrointestinal intubation, liquid meals of unusual composition or left lateral decubitus posture) to define mechanisms. To our knowledge, a more prolonged study in the daily practice of a three times daily intake of orlistat in the target group of obese subjects is lacking. Therefore, we decided to test the hypothesis of a decreased CCK release and an accelerated gastric emptying by lipase inhibition in patients entering a double-blind, placebocontrolled study, at the time of randomization, and 1 and 12 months after randomization to placebo or orlistat. As the institution of an energy-and fat-restricted diet in itself might interfere with CCK release and gastric emptying, the effects of 1 month of dietary compliance, prior to enrolment into the double-blind study, were also investigated.
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Patients and methods
Subjects with a body mass index (BMI) between 28 and 43 kg/m 2 , and 18 years or older, were invited to enter a weight loss program and simultaneously to participate in a study examining gastric emptying. The weight loss program consisted of an energy-and fat-restricted diet, exercise and behavioral modification. Patients were instructed how to increase their daily activities in leisure time. Moreover, aerobics classes twice weekly in the hospital were, although optional, part of the weight loss program. In the first month, patients also received placebo medication (single-blind part of the study). After having demonstrated compliance with the diet as evaluated by the dietician and intake of medication by pill counting, they were randomized to treatment with placebo, 60 mg orlistat or 120 mg orlistat, three times daily (double-blind part of the study).
The first gastric emptying scintigraphy was performed at the start (T0) and the second after 1 month of diet and placebo medication (T1). To investigate the influence of lipase inhibition, the gastric emptying studies were repeated after 1 month (T2) and 1 year (T3) after randomization to study medication. Exclusion criteria consisted of the usual contraindications for intended weight loss (severe medical illness, malignancy within 5 years, immune-compromised status, recent myocardial infarction, pregnancy and lactation). More specific orlistat-related contraindications consisted of significant gastrointestinal disorders, cholelithiasis, nephrolithiasis, pancreatic disease and use of medications, which could be influenced by fat malabsorption such as anticoagulant therapy. As for the present study, patients with a history of peptic ulcer disease, gastrectomy, vagotomy, bariatric surgery, diabetes mellitus, bulimia nervosa or dyspeptic symptoms were excluded. The use of drugs, which interfered with gut motility, was not allowed. The Medical Ethical Committee approved the study protocol and written informed consent was obtained from each individual before study entry.
At the time of the gastric emptying study, body weight and height were measured. The dietician took a dietary history and patients were asked to submit a 4-day food diary, including 2 weekdays and 2 weekend days, each month. The dietician discussed the diary and compliance with the diet at length with the patient and evaluated the dietary adherence more accurately at the start, after 1 month of diet, and after 1 month and 1 year of drug randomization by calculating the energy and macronutrient intake recorded in the 4-day food diary, using the extended computerized version of the Netherlands Food Table ( NEVO foundation, The Hague, the Netherlands). The WHO formula was used to calculate the basal metabolic rate, to be multiplied by 1.3 to obtain the estimated daily energy expenditure in MJ/day. The prescribed diet equaled the estimated total energy expenditure minus 2.5 MJ (600 kcal) with a minimum intake of 5 MJ (1200 kcal). The fat content was adjusted to 30% of the total energy intake. After 6 months, the diet had to be adjusted to promote further weight loss. As body weight was lost, the energy requirements decreased proportionally and therefore, for each kg of weight loss, a reduction of 125 kJ/day (30 kcal/ day) was required with a maximal reduction of 1250 kJ Lipase inhibition and gastric emptying in obesity EMH Mathus-Vliegen et al (300 kcal). Those with an already minimal intake were allowed to reduce their intake to 4.2 MJ (1000 kcal). As to physical activity, patients filled out a questionnaire about the types of activities they practiced, how often (once a week or less to eight times or more per week, on a fivepoint scale) they practiced and the duration of each session (1-15 to 491 min, on a five-point scale).
Gastric emptying scintigraphy
Gastric emptying was investigated for solids and fluids. 15 Patients came to the hospital after an overnight fast. In, respectively, with a 10% window. The data were acquired and processed on a Hermes (Nuclear Diagnostics, Sweden) acquisition and processing station.
A cobalt-67 point source was attached to the patient's clothing on the right side above the stomach for motion correction. The patients were positioned as close as possible in front of the gamma camera in a comfortable chair to minimize body movements. They remained seated for the whole period of the examination. First, the downscatter fraction was determined on a 2-min acquisition of 111 Incounts in the 99m Tc-window after the patient ingested a sip of the liquid test meal. Then, the patient ate the pancake and drank the glucose solution within 5 min. During 90 min gastric emptying was measured in the anterior position using a 1-min frame dynamic acquisition. Subsequently, the chair was turned to measure a frame in the left lateral position. In this position, a 99m Tc point source (p2 MBq) was placed between xiphoid and umbilicus as a marking of the anterior abdominal wall. Then, the patient drank 150 ml of water containing 4 MBq 99m
Tc-HSA-colloid and a 2-min left lateral frame image was acquired. The quantitative analysis of the digital imaging was corrected for decay, movements, downscatter, and attenuation. 39 The lag phase was determined as the time between the intake of the pancake and the first appearance of radioactivity in the duodenum minus the time needed for ingestion. The lag phase (min), the T50 for liquids (the time required to empty 50% of liquids (min)) and the rate of solid emptying (%/h) were the parameters of interest. Normal values of our laboratory reference group of 10 healthy normal-weight subjects (4 M, 6 F; mean (s.d.) age 33 (10) years) are T50 for fluids 39.4 (24.1) min, % emptying for solids 37.9 (8.8) %/h, T50 for solids 84.3 (29.4) min). To exclude interobserver variation, one investigator evaluated all studies.
Cholecystokinin release and subjective feelings of satiety For logistic reasons (i.e., gastric emptying scintigraphy was performed in the weekend; patients had to remain seated which impeded blood sampling and filling out the forms), cholecystokinin (CCK) release and feelings of satiety in response to the same pancake meal and drug was measured on a separate day, thereby also avoiding effects of stress on gastric emptying. 41 Blood samples for CCK levels were taken, twice in the fasting basal state and at 15 min intervals, up to 1 h after the consumption of the test meal. One hour was chosen because the peak value of CCK was reached after 45 min in 75% and within 60 min in all subjects (unpublished data). Plasma concentrations of CCK were measured using a sensitive and specific radioimmunoassay using antibody T204. 42 The detection limit of the assay is 0.5 pmol/l. The fasting CCK was calculated as the mean of the two fasting levels. Also the highest CCK level (peak CCK) and incremental CCK (highest CCK minus basal CCK) were analyzed. Blood samples were stored in ice, processed and maintained at -201C until measurement. Samples of each series were collected and assayed in one run. In addition, CCK secretion was calculated as the area under the plasma CCK concentration time curve using the trapezoidal rule (AUC: pM*60 min).
To investigate the satiating effects of CCK, wishes to eat, hunger, fullness and prospective feeding intentions were scored on a validated 100 mm Visual Analogue Scale (VAS) immediately after blood sampling. 43 The questions asked were: How strong is your desire to eat (very weak ( ¼ 0 mm) to very strong ( ¼ 100 mm))? How hungry do you feel (not at all to very hungry)? How full do you feel (not at all to very full)? How much food do you think you can eat (nothing at all to very much)? The area under the postprandial time curve for each of the feelings was calculated using the trapezoidal rule (AUC).
Statistical analysis
Intended to be an observational study, no power analysis was performed. Descriptive values are given as means7standard deviation (s.d. and the meal-stimulated CCK release did not change. However, the desire to eat and feelings of hunger increased and the sense of fullness decreased significantly. There was no correlation between the scales of satiety and CCK release. The gastric emptying of fluids and solids did not change.
The influence of diet and lipase inhibition on CCK release, satiety and gastric emptying All subjects complied with the intake of medication. Significantly more patients in the 120 mg orlistat group reported fatty or oily stools in the first month compared with placebo-treated subjects, which persisted for 12 months (Table 2) . Also, fecal urgency and abdominal pain occurred more frequently in the orlistat-treated group (NS).
Placebo treatment (Table 3) . Placebo-treated patients lost a mean (s.e.) 1.2 (0.42) kg or 1.0 (0.38)% of initial weight in the first month and 10.4 (2.84) kg or 9.9 (2.76)% in the first year. The significantly decreased intake of energy and fat, instituted in the 4-week run-in period, was well maintained Table 1 Comparison of subjects before (T0) and 1 month after (T1) the start of the weight loss program consisting of an energy-and fat-reduced diet and singleblind placebo medication 
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EMH Mathus-Vliegen et al and decreased even further over the following 12 months with a significant decrease in fat, although Bonferroni's correction for multiple testing removed this significance. In the first month, the meal-stimulated CCK release showed a borderline significant decline (P ¼ 0.05) but feelings of satiety did not change. No significant differences in gastric emptying were seen albeit a tendency to a faster solid and fluid emptying was noticed. After 1 year, the CCK values were back to or slightly above the levels at the start. Subjects reported lower levels of desire to eat and feeling hungry and showed less prospective feeding intentions (NS). The rate of solid emptying decreased significantly with 8.3 (1.89) %/h. Treatment with orlistat 120 mg (Table 4) . Patients treated with 120 mg orlistat lost a mean (s.e.) of 2.5 (0.44) kg or 2.5 (0.47)% of initial weight in the first month and 9.8 (1.37) kg or 9.9 (1.35)% in the first year. In the course of the study, patients were likely to more severely restrict their diet in energy and fat.
In the first month, the basal CCK value and the mealstimulated CCK secretion declined significantly without an impact on satiety. Gastric emptying did not change significantly although a faster emptying of solids was noticed. At the end of the first year, the basal CCK recovered to some extent and stimulated CCK release remained to be lower. The time needed to peak for CCK was significantly shorter and feelings of fullness were less after 1 year, but the significance was removed by correction for multiple testing. No effects on gastric emptying were noticed.
Comparison between the 2 treatment groups
At the time of randomization (T1), the two groups were comparable in every respect. Also, the changes in the 1-month period of diet and single-blind placebo treatment preceding the randomization were not different in the groups that were later randomized to placebo or 120 mg orlistat.
Analysis of the magnitude of changes over time in the two groups showed a significantly greater weight loss in kilograms, in percentage initial weight loss and BMI units in the 120 mg orlistat group compared with the placebo group after 1 month of treatment without any difference after 1 year. Proportional changes in intakes of energy, fat and protein were not different. Changes in basal, peak and incremental CCK were not different and as to the CCK secretion, only the time to peak was shorter in the 120 mg orlistat group after 1 year when compared to placebo. Changes in satiety scores and gastric emptying were similar. Values are given as means7s.d. Probability levels are given for pair-wise comparisons. When Bonferroni's correction removed the significance, the probability level is reported in parentheses. Lipase inhibition and gastric emptying in obesity EMH Mathus-Vliegen et al Physical activity tended to be higher in placebo-treated subjects, but this was only significant for the total number of activities after the first month of randomization.
Discussion
We hypothesized two entirely divergent effects of lipase inhibition. On the one hand, the permissive action of partially hydrolyzed fat on CCK release in the duodenum may be impeded by the inhibition of gastric lipase. Furthermore, the hydrolysis of fat in the duodenum may be hindered by the inhibition of pancreatic lipase resulting in a diminished fatty acid liberation and CCK secretion. Thereby, orlistat might cause a lower CCK release with a decreased feedback inhibition of gastric emptying and thus a faster gastric emptying as shown by Meyer et al. 44 in dogs.
However, on the other hand, a 30% inhibition of fat hydrolysis by orlistat would result in a high load of unabsorbed fat in the lower intestine which might then trigger the ileal brake with a negative feedback on gastric emptying with a delayed gastric emptying as a result. [45] [46] [47] The latter hypothesis required the measuring of fat in the stools which would have interfered with the double-blind set-up of the study. Therefore, we started with the first part of our hypothesis.
To disentangle the separate and presumably opposite influences of changes in diet, changes in body weight and lipase inhibition, we decided to split up our study in different phases.
Firstly, we investigated the change in diet from an energyrich, high-fat diet to a moderately energy-and fat-restricted diet. The weight loss observed adequately matched the daily energy deficit of 2.3 MJ. Our test meal, a big size pancake of 445 g and 2.7 MJ with 43% of energy coming from fat, conformed to the usual eating habits of obese subjects. 12, 16 The dietary energy and fat restriction did not result in an altered gastric emptying nor in changes in basal and mealstimulated CCK.
Secondly, in subjects randomized to 1 year of placebo treatment, we could investigate the perpetuating effects of energy and fat reduction as such and found that in the first month after randomization the CCK release diminished in a borderline significant way. This was accompanied by a nonsignificant faster solid emptying. After 1 year, basal and stimulated CCK levels were restored to or even surpassed the values at the start. At that time, the solid emptying slowed down significantly, suggesting an upregulation and increased sensitivity of CCK receptors. These findings are in keeping with the opposite findings of Cunningham et al. 39 and French et al. 48 with high-fat diets in normal-weight healthy volunteers. Cunningham et al. 39 found that 14 days on a high-fat diet desensitized fat-induced small intestinal regulatory and negative feedback mechanisms, resulting in a faster solid emptying. French et al. 48 discovered a faster gastric emptying on a 14-day high-fat diet with elevated CCK levels, compatible with downregulation and desensitization of CCK receptors. The desensitization of CCK receptors would then explain the rapid gastric emptying, the increased intake of energy and higher plasma CCK profiles. It is difficult to say to what extent in our study the observed ongoing reduction in energy and fat intake in placebotreated subjects and the tendency to a lower desire to eat and less hungriness follows from the satiating effects of CCK or the delayed gastric emptying. Thirdly, we investigated the effects of lipase inhibition added to prolonged dieting. Rather unexpected were our findings in orlistat-treated patients, in whom we suspected a faster solid emptying because of an absent permissive action by fatty acids on CCK release and a lower fatty acid liberation and decreased CCK release, as has been shown by Hildebrand et al. 32 with increasing doses of orlistat and increasing Lipase inhibition and gastric emptying in obesity EMH Mathus-Vliegen et al inhibition of lipase activity in non-obese male subjects. Also, others found a faster solid emptying and a lower CCK release in normal volunteers or in diabetic overweight subjects. [34] [35] [36] [37] 49 These studies, however, investigated the effects of a single dose of 120-200 mg orlistat mixed through a liquid meal of purely fat. Only Borovicka et al. 37 performed a study on gastric emptying and CCK release after a period of 5 days of a standard 3000 kcal diet with 31% of energy from fat combined with the intake of three times daily 120 mg orlistat or placebo. We studied our subjects after 1 month and 1 year of uninterrupted lipase inhibition and observed a small but significant decrease in basal CCK and in CCK secretion in the first month in the 120 mg orlistat group. The CCK release recovered to some extent but did not completely normalize after 1 year. No significant effect on gastric emptying was noticed, although it is worthy of note that gastric emptying, if at all changed, became somewhat faster.
The limitations of our study should be acknowledged. Intended to be an observational study, we did not perform a power analysis and we realize that our study might be underpowered. Subjects on placebo and 120 mg orlistat had similar intakes of energy and fat and similar weight losses as well, whereas lipase-induced fat malabsorption of one-third would have resulted in a 140 kcal greater energy deficit in the orlistat group and thus should have resulted in a greater weight loss. [27] [28] [29] This was not observed and may have been a problem of study power. A suggestion of intestinal adaptation seems less likely as complaints suggestive of steatorrhea persisted till 12 months in the 120 mg orlistat group. Other factors explaining a less favorable weight loss such as a higher age, a long history of weight loss attempts and the presence of co-morbidities were not different between the groups. However, a difference in energy expenditure may account for the difference as placebo subjects reported more physical activities with a non-significant higher frequency and longer duration. They also attended more frequently the aerobic classes in the hospital. Notwithstanding these limitations, our study may be helpful to calculate the adequate size of a study comparing the long-term effects of lipase inhibition of three times 120 mg orlistat versus placebo treatment, to confirm or refute the present findings. We did not expect this outcome and unfortunately, we did not measure gastrointestinal transit times and hormones of interest like PYY and GLP-1.
35, 39 We were not allowed to estimate fecal fat excretion as this might have interfered with the double-blind design of the study. Therefore, we cannot discuss the possibility of opposing influences of lipase inhibition, on the one side resulting in an accelerated gastric emptying through a decreased CCK release and on the other resulting in an activation of the ileal brake by unabsorbed fats leading to a delayed gastric emptying.
In conclusion, we demonstrated an inhibiting effect of energy-and fat-restriction initially on CCK secretion, followed later by a slowing of the rate of gastric emptying, which might be explained by a re-sensitization of CCK receptors by a reduction of intestinal nutrient overload. The unexpected outcome of unchanged gastric emptying in orlistat-treated subjects, in whom we hypothesized an accelerated solid emptying, might benefit obese subjects if one assumes a role of accelerated gastric emptying in the pathogenesis and perpetuation of the disease. To what extent the effect of lipase inhibition on gastric emptying is annulled by the ileal brake of unabsorbed fats and by entero-gastric and entero-pyloric reflexes, activated by pH receptors and chemoreceptors, is the subject of our present research.
